Foundation Medicine, Inc. (FMI) Appoints David J. Daly As Chief Commercial Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today announced the appointment of David J. Daly to the role of chief commercial officer. Mr. Daly brings more than 25 years of proven commercial experience in both emerging and Fortune 500 clinical diagnostics and oncology companies to his new role leading Foundation Medicine's commercial organization. Mr. Daly will report to president and chief executive officer, Michael J. Pellini, M.D.

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.